Endometriosis, the Silent Disease: Molecular Targets, Active Principles, and Drug Delivery Systems

Teworte, Sarah, Luciani, Paola
In: Helvetica Chimica Acta · 2022 · vol. 106(1) · doi:10.1002/hlca.202200132 · W4311193694
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This perspective reviews endometriosis pathophysiology, highlights active principles in development, and discusses drug delivery methods for this debilitating disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abstract In this perspective, we provide a broad overview of pathophysiological processes involved in endometriosis, including the role of inflammation, fibrosis, angiogenesis, hormonal regulation, and genetic factors. For each of the functional changes involved with the etiology of the disease, we showcase a selection of active principles in various stages of preclinical and clinical development. Finally, we highlight the role of drug delivery for endometriosis, particularly oral vs . vaginal administration. In doing so, we wish to draw the community's attention to this debilitating disease and highlight the need for interdisciplinary approaches to endometriosis treatment development.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK